Human immunodeficiency virus and liver disease forum 2012

Kenneth E. Sherman, David Thomas, Raymond T. Chung

Research output: Contribution to journalArticlepeer-review

Abstract

In the United States, more than 1.1 million individuals are infected with the human immunodeficiency virus (HIV). These patients exhibit a high frequency of coinfections with other hepatotropic viruses and ongoing fibrosis, leading to cirrhosis and liver-related mortality. Etiologies of liver disease include viral hepatitis coinfections, drug-related hepatotoxicity, fatty liver disease, and direct and indirect effects from HIV infection, including increased bacterial translocation, immune activation, and presence of soluble proteins, that modulate the hepatic cytokine environment. New treatments for hepatitis C virus (HCV) using direct-acting agents appear viable, though issues related to intrinsic toxicities and drug-drug interactions remain. Recent research suggests that acute HCV infection, unrecognized hepatitis D infection, and hepatitis E may all represent emergent areas of concern. Antiretroviral agents, including those used in recent years, may represent risk factors for hepatic injury and portal hypertension. Key issues in the future include systematic implementation of liver disease management and new treatment in HIV-infected populations with concomitant injection drug use, alcohol use, and low socioeconomic status.

Original languageEnglish (US)
Pages (from-to)307-317
Number of pages11
JournalHepatology
Volume59
Issue number1
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Human immunodeficiency virus and liver disease forum 2012'. Together they form a unique fingerprint.

Cite this